Back to search results

BP1001-A for Advanced or Recurrent Solid Tumors

This study is testing a new drug called BP1001-A, alone and in combination with paclitaxel, for people with advanced or recurrent solid tumors, including ovarian, fallopian tube, endometrial, and peritoneal cancers. The main goal is to find a safe dose of BP1001-A and understand its side effects. You might be able to join if you are an adult (18 or older) with one of these cancers and other treatments haven't worked or aren't an option. You'll also need to be willing to have biopsies before treatment. The study is currently unclear about its recruitment status.

Study design
This is a Phase 1, open-label study, meaning both you and your doctors will know which treatment you are receiving. It plans to enroll about 50 participants.
What's involved
Participants will receive BP1001-A intravenously (IV) twice a week for 4 weeks, for a total of 6 cycles. Some participants will also receive paclitaxel IV weekly for 4 weeks, for 6 cycles. You will also need to have biopsies before treatment.
Compensation
Not stated in the trial record.
Follow-up
The study will look at side effects and dose-limiting toxicities for 30 days after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04196257

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Bio-Path Holdings, Inc.
~50 participants
Updated 2025-03-07 on ClinicalTrials.gov
What's tested:BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Identify Dose Limiting Toxicity (DLT) of BP1001-A
Measured over 30 days
+3 more outcomes measured

Conditions

Solid Tumor, Adult
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Endometrial Cancer
Peritoneal Cancer
Solid Tumor

Explore related trials

Endometrial CarcinomaFallopian Tube CarcinomaMalignant Ovarian NeoplasmMalignant Peritoneal NeoplasmSolid Neoplasm

Where it's being run

4 sites across 3 states
Texas2
Maryland1
Michigan1

Who to contact

Brian Forbes
[email protected]
832-742-1365
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Identify Dose Limiting Toxicity (DLT) of BP1001-A30 days

    Identify DLT of BP1001-A using non-hematologic and and hematologic measures per NCI CTCAE criteria

  • Identify maximum tolerated dose (MTD) of BP1001-A30 days

    Identify MTD based on dose limiting toxicities (DLT) of BP1001-A using non-hematologic and hematologic measures per NCI CTCAE criteria

  • Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-A30 days

    Identify and grade TEAE of escalating doses of BP1001-A using non-hematologic and hematologic measures per NCI CTCAE criteria

  • Identify and grade Treatment-Emergent Adverse Events (TEAE) of BP1001-A in combination with paclitaxel30 days

    Identify and grade TEAE of BP1001-A in combination with paclitaxel using non-hematologic and hematologic measures per NCI CTCAE criteria